Mechanisms of Impaired Regulation by CD4(+)CD25(+)FOXP3(+) Regulatory T Cells in Human Autoimmune Diseases

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2010 Nov 26

PMID 21107346

Citations 344

Authors

Jane Hoyt Buckner

Affiliations

Soon will be listed here.

Abstract

A lack of regulatory T (T(Reg)) cells that express CD4, CD25 and forkhead box P3 (FOXP3) results in severe autoimmunity in both mice and humans. Since the discovery of T(Reg) cells, there has been intense investigation aimed at determining how they protect an organism from autoimmunity and whether defects in their number or function contribute to the development of autoimmunity in model systems. The next phase of investigation - that is, to define the role that defects in T(Reg) cells have in human autoimmunity - is now underway. This Review summarizes our progress so far towards understanding the role of CD4(+)CD25(+)FOXP3(+) T(Reg) cells in human autoimmune diseases and the impact that this knowledge might have on the diagnosis and treatment of these diseases.

Citing Articles

From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases.

Bulliard Y, Freeborn R, Uyeda M, Humes D, Bjordahl R, de Vries D Front Immunol. 2024; 15:1509956.

PMID: 39697333 PMC: 11653210. DOI: 10.3389/fimmu.2024.1509956.

Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs.

Reddy N, Maachi H, Xiao Y, Simic M, Yu W, Tonai Y Science. 2024; 386(6726):eadl4793.

PMID: 39636990 PMC: 11831968. DOI: 10.1126/science.adl4793.

Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function.

Brown M, Thirawatananond P, Peters L, Kern E, Vijay S, Sachs L Diabetologia. 2024; 68(2):397-418.

PMID: 39636437 PMC: 11732877. DOI: 10.1007/s00125-024-06329-8.

Evaluation of CD4 CD25 CD127 Regulatory T-Cells in Different Stages of Psoriatic Arthritis Patients.

Safari R, Shakurnia A, Ghadiri A, Rajaei E, Mowla K, Haidari M Adv Biomed Res. 2024; 13:77.

PMID: 39512405 PMC: 11542692. DOI: 10.4103/abr.abr_359_23.

B-cell and plasma cell activation in a mouse model of chronic muscle pain.

Lenert M, Green A, Merriwether E, Burton M Neurobiol Pain. 2024; 16:100169.

PMID: 39507010 PMC: 11539501. DOI: 10.1016/j.ynpai.2024.100169.

References

Izcue A, Powrie F . Special regulatory T-cell review: Regulatory T cells and the intestinal tract--patrolling the frontier. Immunology. 2007; 123(1):6-10. PMC: 2433286. DOI: 10.1111/j.1365-2567.2007.02778.x. View

Rahman M, Midtling E, Svingen P, Xiong Y, Bell M, Tung J . The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival. J Immunol. 2010; 184(12):7247-56. PMC: 3886856. DOI: 10.4049/jimmunol.0901479. View

Fantini M, Rizzo A, Fina D, Caruso R, Sarra M, Stolfi C . Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology. 2009; 136(4):1308-16, e1-3. DOI: 10.1053/j.gastro.2008.12.053. View

Vargas-Rojas M, Crispin J, Richaud-Patin Y, Alcocer-Varela J . Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus. 2008; 17(4):289-94. DOI: 10.1177/0961203307088307. View

Workman C, Szymczak-Workman A, Collison L, Pillai M, Vignali D . The development and function of regulatory T cells. Cell Mol Life Sci. 2009; 66(16):2603-22. PMC: 2715449. DOI: 10.1007/s00018-009-0026-2. View

Tree T, Roep B, Peakman M . A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop. Ann N Y Acad Sci. 2006; 1079:9-18. DOI: 10.1196/annals.1375.002. View

Astier A, Meiffren G, Freeman S, Hafler D . Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest. 2006; 116(12):3252-7. PMC: 1635165. DOI: 10.1172/JCI29251. View

Vignali D, Collison L, Workman C . How regulatory T cells work. Nat Rev Immunol. 2008; 8(7):523-32. PMC: 2665249. DOI: 10.1038/nri2343. View

Zhang B, Zhang X, Tang F, Zhu L, Liu Y . Reduction of forkhead box P3 levels in CD4+CD25high T cells in patients with new-onset systemic lupus erythematosus. Clin Exp Immunol. 2008; 153(2):182-7. PMC: 2492897. DOI: 10.1111/j.1365-2249.2008.03686.x. View

10.

Suen J, Li H, Jong Y, Chiang B, Yen J . Altered homeostasis of CD4(+) FoxP3(+) regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology. 2008; 127(2):196-205. PMC: 2691785. DOI: 10.1111/j.1365-2567.2008.02937.x. View

11.

Yates J, Rovis F, Mitchell P, Afzali B, Tsang J, Garin M . The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol. 2007; 19(6):785-99. DOI: 10.1093/intimm/dxm047. View

12.

Darrasse-Jeze G, Deroubaix S, Mouquet H, Victora G, Eisenreich T, Yao K . Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med. 2009; 206(9):1853-62. PMC: 2737156. DOI: 10.1084/jem.20090746. View

13.

Ben Ahmed M, Belhadj Hmida N, Moes N, Buyse S, Abdeladhim M, Louzir H . IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol. 2009; 182(11):6763-70. DOI: 10.4049/jimmunol.0801792. View

14.

Baadsgaard O, Fisher G, Voorhees J, Cooper K . The role of immune system in the pathogenesis of psoriasis. J Invest Dermatol. 1990; 95(5 Suppl):32S-34S. DOI: 10.1111/1523-1747.ep12505715. View

15.

Stephens L, Mottet C, Mason D, Powrie F . Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol. 2001; 31(4):1247-54. DOI: 10.1002/1521-4141(200104)31:4<1247::aid-immu1247>3.0.co;2-m. View

16.

Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S . Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol. 2009; 30(1):80-9. DOI: 10.1007/s10875-009-9345-1. View

17.

Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R . Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007; 110(4):1225-32. DOI: 10.1182/blood-2006-12-064527. View

18.

Quaglino P, Ortoncelli M, Comessatti A, Ponti R, Novelli M, Bergallo M . Circulating CD4+CD25 bright FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients. Dermatology. 2009; 219(3):250-8. DOI: 10.1159/000238305. View

19.

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

20.

Ochs H, Gambineri E, Torgerson T . IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunol Res. 2007; 38(1-3):112-21. DOI: 10.1007/s12026-007-0022-2. View